Activity of porphobilinogen deaminase in peripheral blood mononuclear cells of patients with metastatic cancer
- 1 December 1988
- Vol. 62 (11), 2297-2300
- https://doi.org/10.1002/1097-0142(19881201)62:11<2297::aid-cncr2820621106>3.0.co;2-7
Abstract
Porphobilinogen deaminase (PBGD), one of the enzymes in the pathway of heme synthesis, was found to be elevated in peripheral mononuclear cells of 60% of patients with epithelial tumors and metastatic spread, but only in 14% of patients with tumor and no evidence of metastases. The combination of both high lactic dehydrogenase and high PBGD afforded a sensitivity of 40%, but a specificity of 96% in diagnosing metastatic spread.This publication has 9 references indexed in Scilit:
- Increased Porphobilinogen Deaminase Activity in Patients With Malignant Lymphoproliferative DiseasesJAMA, 1987
- Erythrocyte uroporphyrinogen synthase activity as a possible diagnostic aid in the diagnosis of lymphoproliferative diseasesCancer, 1983
- Human Lymphocyte Subpopulations in Metastatic Neoplasia — Six Years LaterNew England Journal of Medicine, 1983
- Prognostic factors in advanced colorectal carcinomaThe American Journal of Medicine, 1983
- LDH and melanomaCancer, 1983
- Studies in PorphyriaJournal of Clinical Investigation, 1978
- Circulating Tumor Cells in Patients With CarcinomaPublished by American Medical Association (AMA) ,1965